Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond

ABSTRACT: The androgen receptor drives the growth of metastatic castration-resistant prostate cancer. This has led to the development of multiple novel drugs targeting this hormone-regulated transcription factor, such as enzalutamide – a potent androgen receptor antagonist. Despite the plethora of possible treatment options, the absolute survival benefit of each treatment separately is limited to a few months. Therefore, current research efforts are directed to determine the optimal sequence of therapies, discover novel drugs effective in metastatic castration-resistant prostate cancer and define patient subpopulations that ultimately benefit from these treatments. Molecular studies provide evidence on which pathways mediate treatment resistance and may lead to improved treatment for metastatic cast

SUBMITTER: Linder S 

PROVIDER: S-EPMC6215909 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature